Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable ...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer. The mid-stage Study 22 trial ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients battling advanced-stage liver cancer. While the company still requires other ...

Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] Draft guidance Technology appraisal guidance 3 March ...

Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] Draft guidance Technology appraisal guidance 18 February 2025 Durvalumab with tremelimumab for untreated advanced or ...

It compared the therapy as a single agent and in conjunction with Imjudo (tremelimumab) against a placebo in LS-SCLC subjects who did not progress following chemoradiation therapy. AstraZeneca ...

Crested Moa (Pachyornis australis). Credit: From the series- ExSnct Birds of New Zealand., 2005, Masterton, by Paul MarSnson. Te Papa (2006-0010-1-19). CC BY-NC-ND 4.0, edited New research reveals ...

Durvalumab in combination with Tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), it added. The receipt of this permission paves way for the ...

4 The nice thing about this trial is you continued on the chemotherapy for up to 4 cycles with the durvalumab [Imfinzi] and tremelimumab [Imjudo] every 3 weeks, but then the CTLA-4 inhibitor ...

You can view the full content in the following formats: ...